TG Therapeutics (TGTX) Earnings Date, Estimates & Call Transcripts $25.06 -0.07 (-0.28%) (As of 10/31/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 6EstimatedActual EPS (Aug. 6) $0.04 Beat By $0.08 Consensus EPS (Aug. 6) -$0.04 Conference Call TranscriptEarnings Press Release Get TG Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for TGTX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueTGTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TGTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, TG Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.02)($0.02)($0.02)Q2 20242($0.08)($0.04)($0.06)Q3 20242$0.03$0.04$0.04Q4 20242$0.10$0.11$0.11FY 20248$0.03$0.09$0.06TGTX Earnings Date and InformationTG Therapeutics last announced its quarterly earnings results on August 6th, 2024. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.08. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. Its revenue was up 357.0% compared to the same quarter last year. TG Therapeutics has generated $0.23 earnings per share over the last year ($0.23 diluted earnings per share) and currently has a price-to-earnings ratio of 41.1. Earnings for TG Therapeutics are expected to grow by 538.46% in the coming year, from $0.13 to $0.83 per share. TG Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off prior year's report dates.Read More TG Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/6/2024(Estimated)------- 8/6/2024Q2 2024($0.04)$0.04+$0.08$0.04$65.92 million$73.47 million 5/1/2024Q1 2024($0.05)($0.07)($0.02)($0.07)$54.60 million$63.47 million 2/28/2024Q4 2023($0.12)($0.09)+$0.03($0.09)$40.06 million$43.97 million 11/1/2023Q3 2023$0.29$0.73+$0.44$0.73$23.91 million$165.80 million 8/1/2023Q2 2023($0.26)($0.34)($0.08)($0.34)$17.39 million$16.07 million 5/1/2023Q1 2023($0.36)($0.28)+$0.08($0.28)$3.38 million$7.80 million Get the Latest News and Ratings for TGTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/2023Q4 2022($0.26)($0.39)($0.13)($0.39)$0.04 million$0.08 million 11/10/2022Q3 2022($0.33)($0.26)+$0.07($0.26)$3.37 million$0.09 million 8/8/2022Q2 2022($0.49)($0.30)+$0.19($0.30)$0.09 million$0.59 million5/10/2022Q1 2022($0.55)($0.51)+$0.04($0.51)$1.54 million$2.02 million3/1/2022Q4 2021($0.62)($0.70)($0.08)($0.70)$9.90 million$2.32 million 11/4/2021Q3 2021($0.56)($0.65)($0.09)($0.65)$3.23 million$2.03 million 8/1/2021Q2 2021($0.48)($0.59)($0.11)($0.59)$3.69 million$1.55 million 5/10/2021Q1 2021($0.52)($0.69)($0.17)($0.69)$0.99 million$0.79 million 3/2/2021Q4 2020($0.57)($0.71)($0.14)($0.71)$0.04 million$0.04 million 11/9/2020Q3 2020($0.41)($0.73)($0.32)($0.73)$0.04 million$0.04 million8/10/2020Q2 2020($0.32)($0.47)($0.15)($0.47)$0.04 million$0.04 million 5/11/2020Q1 2020($0.36)($0.48)($0.12)($0.48)$0.04 million$0.04 million3/3/2020Q4 2019($0.45)($0.44)+$0.01($0.32)$0.04 million$0.04 million 11/12/2019Q4($0.36)($0.69)($0.33)($0.65)$0.04 million$0.04 million TG Therapeutics Earnings - Frequently Asked Questions When is TG Therapeutics's earnings date? TG Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates. Learn more on TGTX's earnings history. Did TG Therapeutics beat their earnings estimates last quarter? In the previous quarter, TG Therapeutics (NASDAQ:TGTX) reported $0.04 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.04) by $0.08. Learn more on analysts' earnings estimate vs. TGTX's actual earnings. How can I read TG Therapeutics's conference call transcript? The conference call transcript for TG Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does TG Therapeutics generate each year? TG Therapeutics (NASDAQ:TGTX) has a recorded annual revenue of $346.72 million. How much profit does TG Therapeutics generate each year? TG Therapeutics (NASDAQ:TGTX) has a recorded net income of $12.67 million. TGTX has generated $0.23 earnings per share over the last four quarters. What is TG Therapeutics's price-to-earnings ratio? TG Therapeutics (NASDAQ:TGTX) has a trailing price-to-earnings ratio of 41.08 and a forward price-to-earnings ratio of 192.77. What is TG Therapeutics's EPS forecast for next year? TG Therapeutics's earnings are expected to grow from $0.13 per share to $0.83 per share in the next year, which is a 538.46% increase. ` More Earnings Resources from MarketBeat Related Companies Deciphera Pharmaceuticals Earnings Date Sage Therapeutics Earnings Date FibroGen Earnings Date Insmed Earnings Date Viatris Earnings Date Dr. Reddy's Laboratories Earnings Date Sarepta Therapeutics Earnings Date Vaxcyte Earnings Date Catalent Earnings Date Qiagen Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer SpendingGoldman Sachs Earnings Reveal Market Moves Investors Can't IgnoreNike’s Post-Earnings Drop Presents a Buying Opportunity This page (NASDAQ:TGTX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
